Business
Cardiff Oncology Formally Introduces Scientific Advisory Board
- SAB includes recognized leaders with expertise in oncology drug development, pharmaceutical industry dynamics and translational research – - SAB will
About this update from Cardiff Oncology, Inc.
[{"type":"text","content":"- SAB includes recognized leaders with expertise in oncology drug development, pharmaceutical industry dynamics and translational research –\n- SAB will continue to provide insight and guidance on the strategy to advance onvansertib through later-stage clinical development -\nSAN DIEGO, March 6, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today formally introduced the full membership of its Scientific Advisory Board (SAB). The SAB is comprised of a distinguished group of academic and industry experts who bring depth and breadth of knowledge in oncology drug development, clinical trial design, translational science and clinical research. In most cases, these individuals have been advising the Company for several years and will now collectively serve a critical role as we advance the clinical development of onvansertib. The Company anticipates that over time the membership of the SAB may expand to add additional expertise in new indications or stages of clinical development.\n\n \n \n \n \n \n \n\n \n\"We are privileged to work with such accomplished oncology medical and scientific thought leaders who are providing strategic guidance to Cardiff Oncology,\" said Fairooz Kabbinavar, MD, chief medical officer of Cardiff Oncology. \"Our advisory board of highly esteemed experts will contribute unique knowledge and experience to the advancement of onvansertib through later-stage clinical development.\"\nThe Cardiff Oncology Scientific Advisory Board includes:\nScott Kopetz, MD, PhD, FACP (MD Anderson Cancer Center)Heinz-Josef Lenz, MD, FACP (University of Southern California Norris Comprehensive Cancer Center)Christoph Reinhard, PhD, MBA (Independent Consultant in oncology translational research)Adam Schayowitz, PhD, MBA (Pfizer Inc.)Josep Tabernero, MD, PhD (Vall d'Hebron University Hospital / University of Vic)Eric Van Cutsem, MD, PhD (University of Leuven / University Hospitals Gasthuisberg)\"I am honored to serve alongside some of the world's leading experts on this SAB in the development of a novel oncology therapy and the application of biomarkers for precision cancer medicine. The clinical data generated with onvansertib are impressive, as it has been show...